Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease NCT04802733

[Bolt_Upright]

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease NCT04802733 clinicaltrials.gov/ct2/show...

Locations

United States, California

University of California Irvine Recruiting

Orange, California, United States, 92868

Contact: Jennifer Scott 714-456-5956 [e-mail]

United States, New York

Weill Cornell Medical College Recruiting

New York, New York, United States, 10065

Contact: Gabrielle Auerbach 212-746-2474 [e-mail]

Canada, Ontario

Toronto Western Hospital Recruiting

Toronto, Ontario, Canada, M5T 2S8

Contact: Martha Lenis, BHA, CHIM, CCRP 416-603-5800 ext 2797 [e-mail]

[park_bear]

from the clinicaltrials link:

"Detailed Description:

Subjects will undergo surgical transplantation of the dopamine-producing cells under general anesthesia into a part of the brain called the putamen. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year. Safety, tolerability, evidence of cell survival (using MRI and PET scans of the brain), and effect on Parkinson's disease symptoms are assessed for 2 years post-transplant."

[jeffreyn]

This is the BlueRock trial, and they are still recruiting.

Some background info here:

healthunlocked.com/cure-par...

[Hidden]

universityofcalifornia.edu/...